Tecentriq
-
Roche presents five-year survival outcomes for Tecentriq plus chemotherapy in extensive-stage small cell lung cancer
IMbrella A, an extension of the Phase III IMpower133 study, demonstrates the potential for a durable overall survival benefit with…
Read More »